摘要
目的探讨普罗帕酮与美托洛尔治疗川崎病合并心律失常患儿的有效性和安全性。方法选取本院儿科2015年11月至2016年11月收治的川崎病合并心律失常患儿80例,按照随机数字法分为观察组和对照组,每组40例。所有患儿入院后均接受对症支持治疗,并进行心电监护。在此基础上,观察组患儿给予普罗帕酮治疗,对照组患儿给予美托洛尔治疗。比较两组患儿的治疗总有效率,治疗前后C反应蛋白(CRP)、肌钙蛋白(CtnI)、血浆心钠素(ANP)、左心室舒张末期内径(LVED)、左心射血分数(LVEF)、心脏指数(CI)指标的变化及不良反应发生率。结果治疗后,观察组总有效率(95.00%)明显高于对照组(75.00%),差异有统计学意义(P<0.01);两组患儿血清CRP、CtnI及ANP水平均明显低于治疗前,且观察组治疗后各指标的水平明显低于对照组(P<0.05);两组患者治疗后LVED均明显减小,且观察组明显低于对照组,两组患儿LVEF及CI水平均明显高于治疗前,且观察组高于对照组(P<0.05);观察组不良反应发生率为10.00%,低于对照组的12.50%,但两组比较差异无统计学意义。结论普罗帕酮治疗川崎病合并心率失常患儿总有效率更高,能明显减轻炎症水平,改善心肌功能,且不良反应较低,值得临床推广运用。
Objective To investigate the efficacy and safety of propafenone and metoprolol in children with Kawasaki disease complicated with arrhythmia. Methods 80 cases pediatric Kawasaki disease combined with arrhythmia in children were selected as study subjects in our hospital from November 2015 to November 2016, according to the random number method were divided into observation group and control group, with 40 cases in each group. All patients were admitted to hospital after symptomatic support treatment, and ECG monitoring. On this basis, the observation group was given propafenone treatment, the control group was given metoprolol treatment. After treatment, the total effective rate of treatment were compared between the two groups, and the levels of C-reactive protein(CRP), troponin(Ctn I), plasma atrial natriuretic peptide(ANP), left ventricular end diastolic diameter(LVED), left ventricular ejection fraction(LVEF), cardiac index(CI) and the incidence of adverse events were compared between the two groups. Results After treatment, the total effective rate(95.00%) in the observation group was significantly higher than the control group(75.00%), the difference was statistically significant(P<0.01). The levels of serum CRP, Ctn I and ANP in the two groups were significantly lower than before treatment, and the observation group was significantly lower than that of the control group(P<0.05). LVVE was significantly reduced in both groups, and the observation group was significantly lower than the control group, the LVEF and CI levels in two groups were significantly higher than before treatment, and the observation group was higher than the control group(P<0.05). The incidence of adverse reactions in the observation group was 10.00% lower than that in the control group 12.50%, but the difference was not statistically significant. Conclusion Propafenone treatment of Kawasaki disease with arrhythmia children has high total effective rate, can significantly reduce the level of inflammation, improve myocardial function, and the adverse reactions is lower, it is worthy of clinical use.
作者
龚晏梅
梁璐
王莹
Gong Yanmei;Liang Lu;Wang Ying(Department of Hospital Quality Control Office,Chongqing Yubei Maternal and Child Health Hospital,Chongqing,401120,China;Department of Pediatrics,Chongqing Traditional Chinese Medicine Hospital,Chongqing,400021,China;Department of Pediatrics,Chongqing Yubei Maternal and Child Health Hospital,Chongqing,401120,China)
出处
《当代医学》
2020年第15期115-118,共4页
Contemporary Medicine
关键词
小儿川崎病合并心律失常
普罗帕酮
美托洛尔
安全性
有效性
Pediatric Kawasaki disease with arrhythmia
Propafenone
Metoprolol
T lymphocyte subsets
Safety
Effectiveness
